Skip to main content
SpringerLink
Log in

Molecular–genetic and clinicopathological prognostic factors in patients with gliomas showing total 1p19q loss: gain of chromosome 19p and histological grade III negatively correlate with patient’s prognosis

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Although 1p19q codeleted gliomas are the most favorable molecular subgroup of lower-grade gliomas, there are cases with early recurrence or short survival. The objective of this study was to elucidate molecular–genetic and clinicopathological prognostic factors in patients with gliomas showing total 1p19q loss. The study included 57 consecutive patients with codeleted gliomas who were operated at Keio University Hospital between 1990 and 2010. These patients were assessed for chromosomal copy number aberrations, promoter methylation status of the O6-methylguanine-DNA methyltransferase gene (MGMT), and demographic and clinicopathological prognostic factors in diffuse gliomas. No significant difference was observed in the overall survival (OS) of the patients with respect to age (≥40 years vs. <40 years), degree of resection, maximum tumor diameter (≥5 cm vs. <5 cm), histological subtype, and MGMT promoter methylation status. Gain of chromosome 19p and grade III histology were associated with shorter OS (P = 0.019, 0.061, respectively). Gain of 19p and histological grade III might be negative prognostic factors for the patients with gliomas showing total 1p19q loss. Further investigation is warranted to confirm these notions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Hayashi S, Sasaki H, Kimura T, Abe T, Nakamura T, Kitamura Y, Miwa T, Kameyama K, Hirose Y, Yoshida K (2015) Molecular–genetic and clinical characteristics of gliomas with astrocytic appearance and total 1p19q loss in a single institutional consecutive cohort. Oncotarget 6(18):15871–15881

    Article  PubMed  PubMed Central  Google Scholar 

  2. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27:5874–5880. doi:10.1200/JCO.2009.23.6497

    Article  CAS  PubMed  Google Scholar 

  3. Suzuki H, Aoki K, Chiba K, Sato Y, Shiozawa Y, Shiraishi Y, Shimamura T, Niida A, Motomura K, Ohka F, Yamamoto T, Tanahashi K, Ranjit M, Wakabayashi T, Yoshizato T, Kataoka K, Yoshida K, Nagata Y, Sato-Otsubo A, Tanaka H, Sanada M, Kondo Y, Nakamura H, Mizoguchi M, Abe T, Muragaki Y, Watanabe R, Ito I, Miyano S, Natsume A, Ogawa S (2015) Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 47:458–468. doi:10.1038/ng.3273

    Article  CAS  PubMed  Google Scholar 

  4. Brad DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA et al (2015) The Cancer Genome Atlas Research Network: Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372:2481–2498. doi:10.1056/NEJMoa1402121

    Article  Google Scholar 

  5. Zulch KJ (1979) Histological typing of tumours of the central nervous system. World Health Organization, Genova

    Google Scholar 

  6. Kleihues P, Burger PC, Scheithauer BW (1993) Histological typing of tumours of the central nervous system. World Health Organization. 2nd edn. Springer, Berlin

    Book  Google Scholar 

  7. Kleihues P, Cavanee W (2000) Pathology and genetics of tumours of the nervous system. World Health Organization. IARC Press, Lyon

    Google Scholar 

  8. Louis DN, Ohgaki H, Wiestler OD, Cavanee WK (2007) WHO classification of tumours of the central nervous system. World Health Organization. 4th edn. International Agency for Research on Cancer, Lyon

    Google Scholar 

  9. Sasaki H, Zlatescu MC, Betensky RA, Ino Y, Cairncross JG, Louis DN (2001) PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol 159:359–367. doi:10.1016/S0002-9440(10)61702-6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Kitamura Y, Sasaki H, Kimura T, Miwa T, Takahashi S, Kawase T, Yoshida K (2013) Molecular and clinical risk factors for recurrence of skull base chordomas: gain on chromosome 2p, expression of brachyury, and lack of irradiation negatively correlate with patient prognosis. J Neuropathol Exp Neurol 72:816–823

    Article  CAS  PubMed  Google Scholar 

  11. Hirose Y, Aldape K, Takahashi M, Berger MS, Feuerstein BG (2001) Tissue microdissection and degenerate oligonucleotide primed-polymerase chain reaction (DOP-PCR) is an effective method to analyze genetic aberrations in invasive tumors. J Mol Diagn 3:62–67. doi:10.1016/S1525-1578(10)60653-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Miwa T, Hirose Y, Sasaki H, Ezaki T, Yoshida K, Kawase T (2011) Single-copy gain of chromosome 1q is a negative prognostic marker in pediatric nonependymal, nonpilocytic gliomas. Neurosurgery 68: 206–212

    Article  PubMed  Google Scholar 

  13. Ezaki T, Sasaki H, Hirose Y, Miwa T, Yoshida K, Kawase T (2011) Molecular characteristics of pediatric non-ependymal, nonpilocytic gliomas associated with resistance to temozolomide. Mol Med Rep 4: 1101–1105. doi:10.3892/mmr.2011.573

    CAS  PubMed  Google Scholar 

  14. Hirose Y, Sasaki H, Abe M, Hattori N, Adachi K, Nishiyama Y, Nagahisa S, Hayashi T, Hasegawa M, Yoshida K (2013) Subgrouping of gliomas on the basis of genetic profiles. Brain Tumor Pathol 30:203–208. doi:10.1007/s10014-013-0148-y

    Article  CAS  PubMed  Google Scholar 

  15. Sasaki H, Hirose Y, Yazaki T, Kitamura Y, Katayama M, Kimura T, Fujiwara H, Toda M, Ohira T, Yoshida K (2015) Upfront chemotherapy and subsequent resection for molecularly defined gliomas. J Neurooncol 124(1):127–135. doi:10.1007/s11060-015-1817-y

    Article  CAS  PubMed  Google Scholar 

  16. Chang EF, Smith JS, Chang SM, Lamborn KR, Prados MD, Butowski N, Barbaro NM, Parsa AT, Berger MS, Mcdermott MM (2008) Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. J Neurosurg 109:817–824. doi:10.3171/JNS/2008/109/11/0817

    Article  PubMed  Google Scholar 

  17. Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, Áfra D, Cornu P, Bolla M, Vecht C et al (2002) Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20:2076–2084. doi:10.1200/jco.2002.08.121

    Article  PubMed  Google Scholar 

  18. Sanai N, Berger MS (2008) Glioma extent of resection and its impact on patient outcome. Neurosurgery 62: 753–766. doi:10.1227/01.neu.0000318159.21731.cf

    Article  PubMed  Google Scholar 

  19. Smith JS, Perry A, Borell TJ, Lee HK, O’Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636–645

    Article  CAS  PubMed  Google Scholar 

  20. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Curran W, Mehta M (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31:337–343. doi:10.1200/JCO.2012.43.2674

    Article  CAS  PubMed  Google Scholar 

  21. Committee of Brain Tumor Registry of Japan Report of Brain Tumor Registry of Japan (2001–2004) (2014) Neurol Med Chir 54:9–102

  22. Baumert BG, Mason WP, Ryan G, Bromberg JE, van den Bent, Hoang-Xuan K, et al (2013) Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss) low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033). J Clin Oncol 31 (suppl; abstr 2007)

  23. Jiang H, Ren X, Zhang Z, Zeng W, Wang J, Lin S (2014) Polysomy of chromosomes 1 and 19: an underestimated prognostic factor in oligodendroglial tumors. J Neuro-Oncol 120:131–138. doi:10.1007/s11060-014-1526-y

    Article  CAS  Google Scholar 

  24. Wiens AL, Cheng L, Bertsch EC, Johnson KA, Zhang S, Hattab EM (2012) Polysomy of chromosomes 1 and/or 19 is common and associated with less favorable clinical outcome in oligodendrogliomas: Fluorescent in situ hybridization analysis of 84 consecutive cases. J Neuropathol Exp Neurol 71:618–624. doi:10.1097/NEN.0b013e31825b5f7a

    Article  CAS  PubMed  Google Scholar 

  25. Cheung HC, Hai T, Zhu W, Baggerly KA, Tsavachidis S, Krahe R, Cote GJ (2009) Splicing factors PTBP1 and PTBP2 promote proliferation and migration of glioma cell lines. Brain 132:2277–2288. doi:10.1093/brain/awp153

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors thank Ms. Naoko Tsuzaki and Ms. Tomoko Muraki for their technical assistance. The authors also greatly thank Dr. Takayuki Abe from the Center for Clinical Research, Department of Preventive Medicine and Public Health, Keio University School of Medicine for the instruction of the statistical analyses.

Funding

This study was funded by Grant-in-Aid for Scientific Research (KAKENHI) by The Ministry of Education, Culture, Sports, Science and Technology and The Japan Society for the Promotion of Science (Grant Numbers 20591721, 23592141, 25462278).

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, Japan

    Saeko Hayashi, Kazunari Yoshida & Hikaru Sasaki

  2. Department of Neurosurgery, Saiseikai Utsunomiya Hospital, 911-1 Takebayashi, Utsunomiya, Tochigi, Japan

    Yohei Kitamura

  3. Department of Neurosurgery, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, Japan

    Yuichi Hirose

Authors
  1. Saeko Hayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yohei Kitamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuichi Hirose
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kazunari Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hikaru Sasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hikaru Sasaki.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Ethical approval

All procedures performed in the present study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hayashi, S., Kitamura, Y., Hirose, Y. et al. Molecular–genetic and clinicopathological prognostic factors in patients with gliomas showing total 1p19q loss: gain of chromosome 19p and histological grade III negatively correlate with patient’s prognosis. J Neurooncol 132, 119–126 (2017). https://doi.org/10.1007/s11060-016-2344-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-016-2344-1

Keywords

Search

Navigation